In addition, we studied the relationships among these lncRNAs, programmed death-ligand 1 (PD-L1) expression, and the TME to determine whether the signature could be used to predict the response of BC patients to ICIs and immunotherapy. This evidence concerns the gene CD274 and breast cancer.